Dual IO 2021
Phase 2 Trial of Nivolumab plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: Spanish Multidisciplinary Melanoma Group (GEM-1402)
Nivolumab plus ipilimumab demonstrated improvement in overall survival for patients with metastatic uveal melanoma.
Nivolumab plus ipilimumab demonstrates deep and sustained confirmed responses for patients with metastatic uveal melanoma.
The combination of nivolumab and ipilimumab offers deep and sustained responses and improved overall survival in malignant uveal melanoma.
Nivolumab plus Relatlimab in the Neoadjuvant and Adjuvant Settings for Patients with Resectable Clinical Stage III Melanoma
Neoadjuvant and adjuvant treatment with nivolumab plus relatlimab for resectable stage III melanoma achieved high pathologic complete response and major pathologic response rates.
Nivolumab plus Ipilimumab as First-Line Therapy in Patients with Advanced Melanoma: 6.5-Year Update from CheckMate-067
In a 6.5-year update of CheckMate-067, durable improvements in overall survival, progression-free survival, and objective response rate were observed with nivolumab plus ipilimumab over nivolumab alone as first-line therapy in patients with advanced melanoma, with no new safety signals.
Relatlimab plus Nivolumab versus Nivolumab Alone in First-Line Advanced Melanoma: Primary Results from RELATIVITY-047
First-line treatment with relatlimab plus nivolumab demonstrated a statistically significant progression-free survival benefit compared with nivolumab monotherapy in patients with advanced melanoma.
Dual immunotherapy provides significant and durable benefits as first-line treatment and as neoadjuvant therapy in advanced melanoma.
Phase 2 Study of the Anti-TIGIT Antibody Tiragolumab plus Atezolizumab versus Placebo plus Atezolizumab as First-Line Treatment in Patients with PD-L1–Selected NSCLC: CITYSCAPE
Treatment for NSCLC using the combination of tiragolumab plus atezolizumab was more effective than treatment with placebo plus atezolizumab.
COAST: An Open-Label, Randomized, Phase 2 Platform Study of Durvalumab Alone or in Combination with Novel Agents in Patients with Locally Advanced, Unresectable, Stage III NSCLC
Durvalumab plus either oleclumab or monalizumab improved overall response rate, progression-free survival, and 10-month progression-free survival in locally advanced, unresectable, stage III NSCLC.
First-Line Nivolumab plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma: 3-Year Update from CheckMate-743
The phase 3 CheckMate-743 trial demonstrated survival improvement over 3 years with first-line nivolumab plus ipilimumab for patients with unresectable malignant pleural mesothelioma.